International Journal of Multiple Sclerosis and Related Disorders

Aims and Scope

International Journal of Multiple Sclerosis and Related Disorders (JSC) is a peer-reviewed, open-access journal dedicated to publishing the latest advancements in the diagnosis, treatment, and management of multiple sclerosis (MS) and related neurological conditions. JSC serves as a global platform for clinicians, researchers, and healthcare professionals to share cutting-edge research, clinical insights, and innovative approaches to understanding and treating MS and its associated disorders.  
 

Scope and Focus:

JSC covers a broad spectrum of topics related to multiple sclerosis and its related neurological conditions, including but not limited to:  

• Pathophysiology and Disease Mechanisms: Advances in understanding the underlying biology of MS and related disorders.  
• Diagnosis and Biomarkers: Novel diagnostic techniques, imaging, and biomarker discovery.  
• Therapeutic Approaches: Pharmacological treatments, immunotherapies, and emerging therapeutic strategies.  
• Neuroimmunology and Inflammation: The immune system’s role in MS and autoimmune neurological diseases.  
• Epidemiology and Risk Factors: Genetic, environmental, and lifestyle factors influencing MS progression.  
• Disease Progression and Prognosis: Studies on relapse patterns, disability progression, and long-term outcomes.  
• Rehabilitation and Symptom Management: Strategies to manage symptoms such as fatigue, pain, and cognitive impairment.  
• Neuropsychology and Mental Health: Cognitive dysfunction, depression, and psychological impacts of MS.  
• Pediatric and Atypical MS: Research on early-onset and uncommon forms of MS and related disorders.  
• Emerging Technologies and Artificial Intelligence in MS Research: Innovations in neuroimaging, digital health, and artificial intelligence applications.  
   

We have included a list of keywords to indicate the scope of the journal. If you have any questions, please do not hesitate to contact us at [email protected]

• Biochemistry
• Genetics
• Psychology
• Virology
• Autoimmune disease
• Atrophy
• Nootropics
• Diplopia
• Neuroplasticity
• Exacerbation
• Comorbidity
• Microbiome
• Accelerometer
• Neuromyelitis optica
• Neurology
• Immunology
• Lymphopenia
• Adrenoleukodystrophy
• Demyelination
• Dysesthesias
• Fingolimod
• Ozanimod
• Brain development
• Causes of multiple sclerosis
• Clinically isolated syndrome
• Neurological assessment
• Types of multiple sclerosis
• Epidemiology and genetics
• Neuroimmunological disorders
• Autoimmune diseases of the central nervous system
• Multiple sclerosis
• Neuroinflammation
• Central nervous system
• Myelin
• Immune system dysfunction
• Relapsing-remitting multiple sclerosis
• Primary progressive multiple sclerosis
• Secondary progressive multiple sclerosis
• Progressive-relapsing multiple sclerosis
• Multiple sclerosis diagnosis
• Magnetic resonance imaging
• Lumbar puncture
• Multiple sclerosis symptoms
• Multiple sclerosis relapses
• Multiple sclerosis treatment
• Disease-modifying therapies
• Interferon beta
• Glatiramer acetate
• Teriflunomide
• Dimethyl fumarate
• Natalizumab
• Alemtuzumab
• Ocrelizumab
• Rituximab
• Cladribine
• Siponimod
• B-cell therapies
• T-cell therapies
• Stem cell therapies
• Multiple sclerosis rehabilitation
• Physical therapy
• Occupational therapy
• Speech therapy
• Cognitive rehabilitation